लोड हो रहा है...
Trametinib with and without pazopanib has potent preclinical activity in thyroid cancer
Multikinase inhibitors (MKIs) targeting VEGF receptors and other receptor tyrosine kinases have shown considerable activity in clinical trials of thyroid cancer. Thyroid cancer frequently exhibits activation of the RAS/RAF/MEK/ERK pathway. In other types of cancer, paradoxical ERK activation has eme...
में बचाया:
| में प्रकाशित: | Oncol Rep |
|---|---|
| मुख्य लेखकों: | , , , , , , , , |
| स्वरूप: | Artigo |
| भाषा: | Inglês |
| प्रकाशित: |
D.A. Spandidos
2015
|
| विषय: | |
| ऑनलाइन पहुंच: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4583528/ https://ncbi.nlm.nih.gov/pubmed/26324075 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/or.2015.4225 |
| टैग : |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|